Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Venetoclax · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Venetoclax + R-GDP | EXPERIMENTAL | - |
| Glofitamab + R-GDP | EXPERIMENTAL | - |
| Tafasitamab + R-GDP | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Venetoclax | DRUG | Dose Level -1: Venetoclax 200 mg/day days 4-8 cycle 1, days 1-5 cycle 2 and 3, + R-GDP Dose Level 1: Venetoclax 200 mg/day days 4-10 cycle 1, days 1-10 cycle 2 and 3, + R-GDP Dose Level 2: Venetoclax 400 mg/day days 4-10 cycle 1, days 1-10 cycle 2 and 3, + R-GDP Dose Level 3: Venetoclax 800 mg/day days 4-10 cycle 1, days 1-10 cycle 2 and 3, + R-GDP |
| Rituximab Injection | DRUG | 375 mg/m2 - Day 1, cycle 1. |
| Rituximab SC | DRUG | 1400 mg fixed dose - Day 1, cycle 2 and 3 |
| Gemcitabine | DRUG | 1000 mg/m2 - Day 1 to day 8 |
| Dexamethasone | DRUG | 40 mg daily - Day 1 to day 4 |
| Cisplatin | DRUG | 75mg/m2 - Day 1 |
| Glofitamab | DRUG | Cycle 1: Glofitamab 2.5 mg (day 8) and 10 mg (day 15) + R-GDP Cycle 2: Glofitamab 30 mg (day 8) + R-GDP Cycle 3: Glofitamab 30 mg (day 8) + R-GDP |
| Tafasitamab | DRUG | Cycle 1: Tafasitamab (12 mg/kg IV day -1, 8, 15) Cycles 2 and 3: Tafasitamab (12 mg/kg IV day 1, 8, 15) |
Inclusion Criteria: * Patients with histologic diagnosis for one of the following histologies according to the World Health Organization: documented at initial diagnosis or at relapse: * Diffuse large cell lymphoma, B-cell (includes primary mediastinal B-cell lymphoma, T-cell rich B-cell lymphom...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Incyte Corporation | INCY | 2 | PHASE2 | Ruxolitinib, Pembrolizumab |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | - | Undisclosed |
Venetoclax is an investigational small molecule being studied for the treatment of relapsed or refractory aggressive B-Cell lymphoma. It is currently in early Phase 1 clinical development as part of a combination therapy master protocol for patients with this condition.
Venetoclax is being developed by Incyte Corporation, which trades under the ticker INCY. The company is conducting clinical research on this drug for B-Cell lymphoma as part of its oncology pipeline.
Venetoclax is in Phase 1 clinical development. It is currently being evaluated in an early Phase 1 trial for patients with relapsed or refractory aggressive B-Cell lymphoma, and it remains an investigational drug that has not been approved.
Venetoclax is being studied in a single clinical trial with the identifier NCT04161248. This trial is a Phase I master protocol of novel combination therapy for patients with relapsed or refractory aggressive B-Cell lymphoma, and it is active but not recruiting participants.
Venetoclax is a distinct investigational drug being developed by Incyte Corporation for B-Cell lymphoma. It is not known to be identical to any other marketed or investigational agent, and it is being studied as a novel combination therapy component.